Equities analysts forecast that Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) will announce $45.67 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Eagle Pharmaceuticals’ earnings. The highest sales estimate is $47.10 million and the lowest is $44.24 million. Eagle Pharmaceuticals posted sales of $46.02 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 0.8%. The business is scheduled to announce its next quarterly earnings report before the market opens on Monday, May 10th.

According to Zacks, analysts expect that Eagle Pharmaceuticals will report full-year sales of $192.40 million for the current fiscal year, with estimates ranging from $183.71 million to $201.10 million. For the next financial year, analysts anticipate that the company will post sales of $224.62 million, with estimates ranging from $202.40 million to $246.85 million. Zacks’ sales averages are a mean average based on a survey of analysts that cover Eagle Pharmaceuticals.

Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its earnings results on Monday, March 1st. The specialty pharmaceutical company reported $0.96 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.42) by $2.38. Eagle Pharmaceuticals had a return on equity of 8.50% and a net margin of 2.65%. The company had revenue of $49.92 million for the quarter, compared to analyst estimates of $50.08 million.

Separately, Zacks Investment Research lowered Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday.

Several institutional investors have recently bought and sold shares of the company. Blair William & Co. IL increased its stake in shares of Eagle Pharmaceuticals by 1.3% in the fourth quarter. Blair William & Co. IL now owns 49,705 shares of the specialty pharmaceutical company’s stock worth $2,315,000 after purchasing an additional 617 shares during the period. Globeflex Capital L P grew its position in Eagle Pharmaceuticals by 2.1% during the fourth quarter. Globeflex Capital L P now owns 34,263 shares of the specialty pharmaceutical company’s stock worth $1,596,000 after buying an additional 713 shares in the last quarter. Oregon Public Employees Retirement Fund grew its position in Eagle Pharmaceuticals by 17.8% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,783 shares of the specialty pharmaceutical company’s stock worth $223,000 after buying an additional 724 shares in the last quarter. Campbell Newman Asset Management Inc. grew its position in Eagle Pharmaceuticals by 8.1% during the fourth quarter. Campbell Newman Asset Management Inc. now owns 10,614 shares of the specialty pharmaceutical company’s stock worth $494,000 after buying an additional 793 shares in the last quarter. Finally, Principal Financial Group Inc. grew its position in Eagle Pharmaceuticals by 1.0% during the fourth quarter. Principal Financial Group Inc. now owns 108,353 shares of the specialty pharmaceutical company’s stock worth $5,046,000 after buying an additional 1,022 shares in the last quarter. Institutional investors and hedge funds own 95.12% of the company’s stock.

NASDAQ EGRX traded down $0.82 during trading on Tuesday, hitting $41.15. 68,006 shares of the company traded hands, compared to its average volume of 118,757. Eagle Pharmaceuticals has a 12 month low of $36.48 and a 12 month high of $56.16. The business has a fifty day simple moving average of $42.64 and a 200 day simple moving average of $46.06. The company has a current ratio of 3.60, a quick ratio of 3.45 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $543.88 million, a P/E ratio of 117.57 and a beta of 0.74.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

Recommended Story: How Do You Calculate Return on Investment (ROI)?

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.